Display options
Cite
Mushti SL, Mulkey F, Tang S, et al. Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. Curr Oncol Rep. 2020;22(11):116doi: 10.1007/s11912-020-00974-z.
Mushti, S. L., Mulkey, F., Tang, S., Singh, H., Lemery, S. J., Goldberg, K. B., Sridhara, R., Keegan, P., Kluetz, P. G., Pazdur, R., Theoret, M. R., & Beaver, J. A. (2020). Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. Current oncology reports, 22(11), 116. https://doi.org/10.1007/s11912-020-00974-z
Mushti, Sirisha L, et al. "Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy." Current oncology reports vol. 22,11 (2020): 116. doi: https://doi.org/10.1007/s11912-020-00974-z
Mushti SL, Mulkey F, Tang S, Singh H, Lemery SJ, Goldberg KB, Sridhara R, Keegan P, Kluetz PG, Pazdur R, Theoret MR, Beaver JA. Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. Curr Oncol Rep. 2020 Aug 27;22(11):116. doi: 10.1007/s11912-020-00974-z. PMID: 32851542.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol Rep. 2020 Aug 27;22(11):116. doi: 10.1007/s11912-020-00974-z.

Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.

Current oncology reports

Sirisha L Mushti, Flora Mulkey, Shenghui Tang, Harpreet Singh, Steven J Lemery, Kirsten B Goldberg, Rajeshwari Sridhara, Patricia Keegan, Paul G Kluetz, Richard Pazdur, Marc R Theoret, Julia A Beaver

Affiliations

  1. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA. [email protected].
  2. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
  3. Oncology Center of Excellence, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
  4. Oncology Center of Excellence (Contractor), Brillient Corporation, Reston, USA.

PMID: 32851542 DOI: 10.1007/s11912-020-00974-z

Abstract

PURPOSE OF REVIEW: This review provides a comprehensive assessment of recent literature reports describing atypical response patterns observed with immune checkpoint inhibitors (ICIs), modifications to response evaluation criteria for ICIs, and treatment beyond progression in clinical trials.

RECENT FINDINGS: Certain response patterns such as durable response, pseudoprogression, hyperprogression, and dissociated responses can be seen with ICI treatment. These patterns carry differing prognoses and are associated with varied factors. There are multiple modifications of standard Response Evaluation Criteria in Solid Tumors (RECIST) that have been proposed to better characterize immunotherapy response; however, standard RECIST1.1 remains most commonly used in clinical trials. Treatment beyond progression varies in frequency and benefit depending on assessment criteria and cancer type. Future research incorporating modified imaging criteria and biomarker assessments may serve to clarify who will benefit most from treatment beyond progression.

Keywords: Atypical response patterns; Immunotherapy; RECIST; Response criteria; Solid tumors; Treatment beyond progression

Substances

MeSH terms

Publication Types